Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.

@article{Maxon1990Re186SnHF,
  title={Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.},
  author={Harry R. Maxon and Louis E. Schroder and Stephen Randall Thomas and Vicki Stover Hertzberg and Edward A. Deutsch and Howard I. Scher and R C Samaratunga and Karen F. Libson and Craig C. Williams and Jonathan S. Moulton},
  journal={Radiology},
  year={1990},
  volume={176 1},
  pages={155-9}
}
Rhenium-186(tin) hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that localizes in areas of osseous metastases in a manner similar to that of standard bone-scanning agents. It also emits beta particles with sufficient energy to be therapeutically useful. A single intravenous injection of about 33 mCi (1,221 MBq) was given to each of 20 elderly patients with advanced skeletal metastases from hormonally resistant prostate cancer. Prompt, significant relief of pain occurred 80… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…